

King's Mill Hospital
Mansfield Road
Sutton in Ashfield
Nottinghamshire
NG17 4JL

Tel: 01623 622515
Join today: www.sfh-tr.nhs.uk

Direct Line: 01623 672232
Our Ref: 1341
E-mail: sfh-tr.foi.requests@nhs.net

31st July 2026

[REDACTED]

Dear Sir/Madam

Freedom of Information Act (FOI) 2000 - Request for Information Reference: Treatment of cancers

I am writing in response to your request for information under the FOI 2000.

I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do not hold the information you have requested. A response to each part of your request is provided below. Please accept our apologies for the delay.

Home, Community, Hospital.

FOI Request / Question	Question Response	Is there an exemption?	Exemption	Exemption Details
1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel (Jevtana or generic cabazitaxel) 1.4 Darolutamide (Nubeqa) 1.5 Enzalutamide (Xtandi) 1.6 Talazoparib (Talzenna) 1.7 Docetaxel 1.8 Relugolix (Orgovyx, Ryeqo) 1.9 Olaparib (Lynparza)	Information not held, Oncology patients are referred to Nottingham University Hospitals. Please contact Nottingham University Hospitals NHS Trust nuhnt.dutyin@nhs.net who may hold this information.			
2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer				
3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st October				

2

Home, Community, Hospital.

2025 to the end of December 2025, or latest 3-months for which data are available? 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi)				
4. How many patients were treated with the following combinations in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) monotherapy 4.3 Olaparib (Lynparza) + Abiraterone				
5. I would be grateful if you could send me the Trust's most recent planning document(s) for the treatment of Prostate Cancer following the publication of NICE Technology Appraisal Guidance TA1130, TA1110, and TA1109, which recommend drug treatment for a wider patient population with prostate cancer.				
6. Is your organisation planning for any changes in service provision following NICE's recommendation of abiraterone for the treatment of people with high-risk, hormone sensitive, non-metastatic prostate cancer? (link to NICE statement -				

3

Home, Community, Hospital.

Patient Experience Team
01623 672222
sfh-tr.pet@nhs.net



We are proud to be
a smoke-free site

Trust Chair Rukshana Kapasi OBE
Chief Executive Jon Melbourne

https://www.england.nhs.uk/publication/abiraterone-acetate-and-prednisolone-for-high-risk-hormone-sensitive-non-metastatic-prostate-cancer-adults/ Yes No				
7. What aspects of service provision will be impacted by NICE'S recommendation of abiraterone for the treatment of people with high-risk, hormone sensitive, non-metastatic prostate cancer Yes / No 7.1 Clinic space / capacity 7.2 Patient education 7.3 Increased provision of care in primary care 7.4 Increased demand for diagnostics 7.5 Governance 7.6 Budgetary 7.7 None				
8. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? 8.1 Abiraterone 8.2 Enzalutamide				

I trust this information answers your request. Should you have any further enquiries or queries about this response please do not hesitate to contact me. However, if you are unhappy with the way in which your request has been handled, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Sally Brook Shanahan, Director of Corporate Affairs, King's Mill Hospital, Mansfield Road, Sutton in Ashfield, Nottinghamshire, NG17 4JL or email sally.brookshanahan@nhs.net.

If you are dissatisfied with the outcome of the internal review, you can apply to the Information Commissioner's Office, who will consider whether we have complied with our obligations under the Act and can require us to remedy any problems. Generally, the Information Commissioner's Office cannot decide unless you have exhausted the internal review procedure. You can find out more about how to do this, and about the Act in general, on the Information Commissioner's Office website at: <https://ico.org.uk/your-data-matters/official-information/>.

Complaints to the Information Commissioner's Office should be sent to FOI/EIR Complaints Resolution, Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF. Telephone 0303 1231113, email casework@ico.org.uk.

If you would like this letter or information in an alternative format, for example large print or easy read, or if you need help with communicating with us, for example because you use British Sign Language, please let us know. You can call us on 01623 672232 or email sfh-tr.foi.requests@nhs.net.

Yours faithfully

Information Governance Team

All information we have provided is subject to the provisions of the Re-use of Public Sector Information Regulations 2015. Accordingly, if the information has been made available for re-use under the [Open Government Licence](#) (OGL) a request to re-use is not required, but the licence conditions must be met. You must not re-use any previously unreleased information without having the consent from Sherwood Forest Hospitals NHS Foundation Trust. Should you wish to re-use previously unreleased information then you must make your request in writing. All requests for re-use will be responded to within 20 working days of receipt.